Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5892
    -0.0013 (-0.22%)
     

  • NZD/EUR

    0.5523
    -0.0022 (-0.39%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.0710
    -0.1830 (-0.20%)
     

Schwab Focuses on Growing Trading Income, Expenses Increase

Zacks Equity Research
Updated

The Charles Schwab Corporation’s SCHW efforts to strengthen trading income and higher interest rates position it well for growth. However, mounting expenses remain a key concern.

Schwab is focused on augmenting trading revenues. For this, it announced several initiatives including lowering basic online equity and ETF trade commissions and reducing fees for the Schwab market cap-weighted index mutual funds. While the initiatives are expected to hurt revenues in the near term, these are aimed at building client base and improving the company’s trading income.

Apart from this, management’s aggressive efforts to expand client base in advisory solutions have been fruitful. Advice solution revenues have been rising for the last several years. Also, the average client assets have been witnessing a rising trend.

Driven by such initiatives, analysts are optimist about the prospects of the company. The Zacks Consensus Estimate for earnings has been raised nearly 1% and 2.1% for 2018 and 2019, respectively, over the last 60 days.

Also, this Zacks Rank #3 (Hold) stock has surged 36.2% in the past year, outperforming 22.6% growth for the industry it belongs to.



However, continued rise in operating expenses remains a primary concern for Schwab. Costs related to compensation and regulatory spending will likely keep overall expenses high in the upcoming quarters.

Also, significant dependence on fee-based revenue streams is a near-term woe for Schwab. This, along with lower degree of capital intensity compared to its peers make us apprehensive.

Some stocks in the same industry worth a look are E*TRADE Financial Corporation ETFC, Evercore Inc. EVR and LPL Financial Holdings Inc. LPLA, with each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for E*TRADE has been revised 9% upward for the current year in the last 60 days. The company’s share price has rallied 30.1% in the past six months.

Evercore has witnessed 7.8% upward earnings estimate revision for 2018 in the last 60 days. Its share price has increased 23.5% in the past six months.

LPL Financial stock has gained 26% over the past six months. Its earnings estimates for 2018 have moved up 27.2% in the last 60 days.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
E*TRADE Financial Corporation (ETFC) : Free Stock Analysis Report
 
The Charles Schwab Corporation (SCHW) : Free Stock Analysis Report
 
Evercore Inc (EVR) : Free Stock Analysis Report
 
LPL Financial Holdings Inc. (LPLA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research